Article: Diagnocure announces fiscal 2007 second quarter results - Quarterly net loss down 29%.

Ticker Symbol: CUR

QUEBEC CITY, June 6 /PRNewswire-FirstCall/ -- DiagnoCure Inc. (TSX: CUR), a leading developer and provider of innovative high-value molecular diagnostic assays for the detection and management of cancer, today announced its financial results for the second quarter ended April 30, 2007.

Highlights of the Quarter

Gen-Probe, DiagnoCure's exclusive sub-licensee for diagnostic applications of the PCA3 genetic marker, is now distributing analyte specific reagents (ASR) for PCA3 in the U.S., and is selling its fully CE-marked PROGENSA(TM) PCA3 in Europe. Major U.S. laboratories now selling PCA3-based tests include; the Dianon unit ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!